Atika Capital Management’s Novo Nordisk NVO Stock Holding History

Atika Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-68,000	Closed	-$9.71M	–	106
2024 Q2	$9.71M	Sell	68,000 -32,500	-32%	-$4.31M	0.95%	35
2024 Q1	$12.9M	Buy	+100,500	New	+$12M	1.27%	28
2023 Q4	–	Sell	-83,500	Closed	-$7.59M	–	89
2023 Q3	$7.59M	Buy	+83,500	New	+$7.36M	1%	42
2023 Q1	–	Sell	-37,178	Closed	-$2.52M	–	88
2022 Q4	$2.52M	Buy	+37,178	New	+$2.18M	0.36%	56

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Atika Capital Management's NVO Position: Q3 2024 in Review

Atika Capital Management sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 68,000 shares — an estimated $9.71M sold.

Atika Capital Management first reported a position in NVO in Q4 2022 and held it in 4 quarters. The position peaked at $12.9M in Q1 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

Atika Capital Management reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
Atika Capital Management sold 68,000 Novo Nordisk shares in Q3 2024, an estimated $9.71M.
Atika Capital Management first reported a position in Novo Nordisk in Q4 2022 and held it in 4 quarters.
Atika Capital Management's Novo Nordisk position peaked at $12.9M in Q1 2024.
1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Atika Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.